GT Biopharma, Inc.GTBPNASDAQ
Loading
Net Income Growth Under PressureDecelerating
Percentile Rank10
Year-over-Year Change
Year-over-year net income growth rate
Percentile
P10
Near historical low
vs 3Y Ago
-44.3x
Contraction
Streak
3 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -835.32% |
| Q3 2025 | -117.31% |
| Q2 2025 | -84.66% |
| Q1 2025 | 79.44% |
| Q4 2024 | -10.67% |
| Q3 2024 | 8.06% |
| Q2 2024 | -63.72% |
| Q1 2024 | 23.50% |
| Q4 2023 | -22.60% |
| Q3 2023 | -21.29% |
| Q2 2023 | -777.53% |
| Q1 2023 | 95.93% |
| Q4 2022 | 18.85% |
| Q3 2022 | -130.98% |
| Q2 2022 | 45.24% |
| Q1 2022 | 69.81% |
| Q4 2021 | -230.50% |
| Q3 2021 | -12.18% |
| Q2 2021 | 83.62% |
| Q1 2021 | -98.73% |
| Q4 2020 | -419.23% |
| Q3 2020 | 83.49% |
| Q2 2020 | -920.02% |
| Q1 2020 | -16.19% |
| Q4 2019 | 95.08% |
| Q3 2019 | -971.28% |
| Q2 2019 | 38.16% |
| Q1 2019 | -6.59% |
| Q4 2018 | 98.21% |
| Q3 2018 | -2496.44% |
| Q2 2018 | 10.01% |
| Q1 2018 | -67.46% |
| Q4 2017 | 95.39% |
| Q3 2017 | -4515.72% |
| Q2 2017 | 44.05% |
| Q1 2017 | -78.79% |
| Q4 2016 | 22.07% |
| Q3 2016 | -335.26% |
| Q2 2016 | -89.49% |
| Q1 2016 | 139.29% |